The 5th edition of the Kisaco Research international Phage Futures Europe Congress will be held in Brussels, Belgium from Tuesday 23rd November till Wednesday 24th November 2021.
What is the 5th Phage Futures Europe Congress and Why attend?
This year’s summit comes together to provide updates on the efficacy of phage therapies and global regulatory frameworks whilst providing insight into recent clinical trial data and the increased commercial applications of phages.
The 5th edition of the Phage Futures Europe Congress introduces face-to-face interactions once again, helping you maximize networking and commercial development with key industry players such as GSK, BiomX, Contrafect, and more. This year, we discuss the viability of phage-derived lysines in therapy, assess the therapeutic application of natural phages vs engineered phages, and explore the clinical data surrounding the magisterial and compassionate use of phages in Europe.
Bacteriophages have seen continued investment and have adapted to global challenges, introducing commercial and marketable prospects for phage application. Phage Futures Europe explores the commercial applications of phages in poultry, aquaculture, biocontrol, and skin microbiome, providing insights into the global design of phage products and acquiring pharmaceutical partnerships.
Countdown to Summit
Who will be at the 5th Phage Futures Europe Congress?
Over 30 speakers from a diversity of fields will be attending.
The summit will bring together individuals from different industries and occupations, such as; academia, biotech, regulatory and governments, service providers, clinicians, and physicians.
Agenda for the 5th Phage Futures Europe Congress 2021
Tuesday 23rd November 2021
Todd Black Senior Director at Biology, Global Alliance at TB Drug Development – Pharmaceutical design and application of phages to maximise efficacy
Dr. Edith Hessel CSO at Eligo Bioscience – Application of phages in the skin microbiome and following pharmaceutical regulatory standards
Cara Casino M.D. Chief Medical Officer at Contrafect, Sandra Giannini Director at Vaccine Discovery at GSK, and Assaf Oran Chief Business Officer at Biomx – The current state of phages and future prospects for the commercialisation of phage
Assaf Oran Chief Business Officer at Biomx – Maintaining efficacy, clinical trial data presentation of the application of BX001, targeting Cutibacterium acnes
Dr. Gina Suh Managing Director at Infectious Diseases at Mayo Clinic – The Safety and toxicity of phage therapy: reviewing animal and clinical studies
Ruby Lin Deputy Director at Phage Australia at University of Sydney – Compassionate use of phages in Australia
Miguel Garcia Co-founder & CEO at Technophage – Bacteriophages for chronic wound treatment, a clinical study of bacteriophage delivery methods
Jean-Paul Pirnay Senior Director at Phage Therapy at Queen Astrid Military Hospital – Implementation of magisterial phage therapy and the regulatory guidelines associated with a novel phage therapy method
Shawna McCallin Managing Director at University of Geneva – Objective view on the progress of clinical trials
Dr. Dave Ousterout Chief Scientific Officer at Locus Biosciences – Clinical trial presentation on the development and application of crPhage products targeting E. Coli in urinary tract infections
Natalie Ma Co-founder of Felix Biotech – Tackling phage resistance and target host range maximisation using AI
David Harper CEO at Evolution Biotechnologies – Bacteriophages as a biocontrol
Dr. Cindy Fevre Director of R&D at Pherecydes Pharma – Clinical application of natural phages in precision phage therapy: A concept applied to French patients within a compassionate treatment program
Lorenzo Corsini CEO at PhagoMed – M477 could prove superior to both SoC antibiotics metronidazole and clindamycin in the treatment of recurring bacterial vaginosis
Chandra Ghose CEO at Bioharmony – Bacteriophage Lysins: Novel, Nontraditional Antimicrobial Treatments for MDR Pathogens
Tristan Ferry Professor of Medicine at University of Lyon – The Phage lysin CF-301 (Exebacase) in patients with staphylococcal prosthetic joint infection: Experience of a referral clinical centre
Wednesday 24th November 2021
Peter Beyer Senior Advisor at WHO – Regulatory standpoint on the progressive routes of phage application
TBA – Forming regulatory basis for phage therapy in Europe
Tobi Nagel Founder of Phages for Global Health – The economics and advocacy of phages globally
Dr. Adam Ostrowski Technical Applications Specialist at Cellexus – Optimise cleaner phage production using single-use technologies
Danish Malik Director of Biotechnology and Biomedical Engineering at Loughborough University – Manufacturing of phages, current challenges in production and possible solutions
Anupuma Hoey CBO at Sensei Biotherapeutics – Phage-Based Vaccine Development in Oncology
Understanding the pharmacokinetics of phages to increase efficiency in delivery
Heather Fairhead CEO at Phico Theraputics – Delivery of phages, understanding the ecological impact of various delivery options of phages
Maintaining the regulatory framework to ensure safety in phage application in food
Mathew Tebeau Chief Operating Officer at Proteon Pharmaceuticals – Bringing phages to a global market: challenges and considerations
Olivia McAuliffe Research Officer at Teagasc Food Research Centre – Application of phages in poultry and its impact on consumer safety
Steven Theriault CEO at Cytophage – Advances in bacteriophage treatments in agriculture processes
The potential for reverse vaccinology in aquaculture
View past events by Kisaco Research